Liver tumors: Monitoring embolization in rabbits with VX2 tumors - Transcatheter intraarterial first-pass perfusion MR imaging

Dingxin Wang, Affaan K. Bangash, Thomas K. Rhee, Gayle E Woloschak, Tatjana Paunesku, Riad Salem, Reed A. Omary, Andrew Christian Larson*

*Corresponding author for this work

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Purpose: To prospectively test the hypothesis that transcatheter intraarterial first-pass perfusion (TRIP) magnetic resonance (MR) imaging can depict serial reductions in rabbit liver tumor perfusion during transcatheter arterial embolization (TAE). Materials and Methods: All experiments had institutional animal care and use committee approval. In four rabbits implanted with eight VX2 liver tumors, catheters were positioned in the hepatic arteries with conventional angiographic guidance. After transfer to the MR imaging suite, serial TAE was performed, with approximately 0.5 million 40-120-μm embolic particles injected at each embolic stage. TRIP MR imaging was performed at baseline and after each subsequent embolic stage (10 minutes between stages). Serial TAE and TRIP MR imaging were repeated until stasis. The first-pass time course of signal enhancement was measured in both tumors and hepatic arteries. Tumor area under the curve (AUC) and maximum upslope (MUS) values, each normalized by arterial input, were measured to assess iterative perfusion reduction. Perfusion measurements across TAE stages were compared with paired t tests and linear regression. Results: AUC decreased from a pre-TAE baseline of 0.408 (95% confidence interval [CI]: 0.330, 0.486) to 0.065 (95% CI: 0.046, 0.085) (P < .001) after TAE. MUS decreased from a pre-TAE baseline of 0.151 (95% CI: 0.121, 0.181) to 0.027 (95% CI: 0.022, 0.031) (P < .001) after TAE. Reductions to AUC and MUS after each embolic stage were statistically significant (P < .006 for each group of paired comparisons). AUC strongly correlated with MUS (r = 0.966, P < .001). Conclusion: TRIP MR imaging can depict serial reductions in liver tumor perfusion during TAE. TRIP MR imaging offers the potential to target functional embolic end points during TAE.

Original languageEnglish (US)
Pages (from-to)130-139
Number of pages10
JournalRadiology
Volume245
Issue number1
DOIs
StatePublished - Oct 1 2007

Fingerprint

Magnetic Resonance Angiography
Magnetic Resonance Imaging
Area Under Curve
Rabbits
Perfusion
Liver
Confidence Intervals
Hepatic Artery
Neoplasms
Animal Care Committees
Matched-Pair Analysis
Linear Models
Catheters

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{c8af7571443449608c5afaba05391f54,
title = "Liver tumors: Monitoring embolization in rabbits with VX2 tumors - Transcatheter intraarterial first-pass perfusion MR imaging",
abstract = "Purpose: To prospectively test the hypothesis that transcatheter intraarterial first-pass perfusion (TRIP) magnetic resonance (MR) imaging can depict serial reductions in rabbit liver tumor perfusion during transcatheter arterial embolization (TAE). Materials and Methods: All experiments had institutional animal care and use committee approval. In four rabbits implanted with eight VX2 liver tumors, catheters were positioned in the hepatic arteries with conventional angiographic guidance. After transfer to the MR imaging suite, serial TAE was performed, with approximately 0.5 million 40-120-μm embolic particles injected at each embolic stage. TRIP MR imaging was performed at baseline and after each subsequent embolic stage (10 minutes between stages). Serial TAE and TRIP MR imaging were repeated until stasis. The first-pass time course of signal enhancement was measured in both tumors and hepatic arteries. Tumor area under the curve (AUC) and maximum upslope (MUS) values, each normalized by arterial input, were measured to assess iterative perfusion reduction. Perfusion measurements across TAE stages were compared with paired t tests and linear regression. Results: AUC decreased from a pre-TAE baseline of 0.408 (95{\%} confidence interval [CI]: 0.330, 0.486) to 0.065 (95{\%} CI: 0.046, 0.085) (P < .001) after TAE. MUS decreased from a pre-TAE baseline of 0.151 (95{\%} CI: 0.121, 0.181) to 0.027 (95{\%} CI: 0.022, 0.031) (P < .001) after TAE. Reductions to AUC and MUS after each embolic stage were statistically significant (P < .006 for each group of paired comparisons). AUC strongly correlated with MUS (r = 0.966, P < .001). Conclusion: TRIP MR imaging can depict serial reductions in liver tumor perfusion during TAE. TRIP MR imaging offers the potential to target functional embolic end points during TAE.",
author = "Dingxin Wang and Bangash, {Affaan K.} and Rhee, {Thomas K.} and Woloschak, {Gayle E} and Tatjana Paunesku and Riad Salem and Omary, {Reed A.} and Larson, {Andrew Christian}",
year = "2007",
month = "10",
day = "1",
doi = "10.1148/radiol.2451061689",
language = "English (US)",
volume = "245",
pages = "130--139",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

Liver tumors : Monitoring embolization in rabbits with VX2 tumors - Transcatheter intraarterial first-pass perfusion MR imaging. / Wang, Dingxin; Bangash, Affaan K.; Rhee, Thomas K.; Woloschak, Gayle E; Paunesku, Tatjana; Salem, Riad; Omary, Reed A.; Larson, Andrew Christian.

In: Radiology, Vol. 245, No. 1, 01.10.2007, p. 130-139.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Liver tumors

T2 - Monitoring embolization in rabbits with VX2 tumors - Transcatheter intraarterial first-pass perfusion MR imaging

AU - Wang, Dingxin

AU - Bangash, Affaan K.

AU - Rhee, Thomas K.

AU - Woloschak, Gayle E

AU - Paunesku, Tatjana

AU - Salem, Riad

AU - Omary, Reed A.

AU - Larson, Andrew Christian

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Purpose: To prospectively test the hypothesis that transcatheter intraarterial first-pass perfusion (TRIP) magnetic resonance (MR) imaging can depict serial reductions in rabbit liver tumor perfusion during transcatheter arterial embolization (TAE). Materials and Methods: All experiments had institutional animal care and use committee approval. In four rabbits implanted with eight VX2 liver tumors, catheters were positioned in the hepatic arteries with conventional angiographic guidance. After transfer to the MR imaging suite, serial TAE was performed, with approximately 0.5 million 40-120-μm embolic particles injected at each embolic stage. TRIP MR imaging was performed at baseline and after each subsequent embolic stage (10 minutes between stages). Serial TAE and TRIP MR imaging were repeated until stasis. The first-pass time course of signal enhancement was measured in both tumors and hepatic arteries. Tumor area under the curve (AUC) and maximum upslope (MUS) values, each normalized by arterial input, were measured to assess iterative perfusion reduction. Perfusion measurements across TAE stages were compared with paired t tests and linear regression. Results: AUC decreased from a pre-TAE baseline of 0.408 (95% confidence interval [CI]: 0.330, 0.486) to 0.065 (95% CI: 0.046, 0.085) (P < .001) after TAE. MUS decreased from a pre-TAE baseline of 0.151 (95% CI: 0.121, 0.181) to 0.027 (95% CI: 0.022, 0.031) (P < .001) after TAE. Reductions to AUC and MUS after each embolic stage were statistically significant (P < .006 for each group of paired comparisons). AUC strongly correlated with MUS (r = 0.966, P < .001). Conclusion: TRIP MR imaging can depict serial reductions in liver tumor perfusion during TAE. TRIP MR imaging offers the potential to target functional embolic end points during TAE.

AB - Purpose: To prospectively test the hypothesis that transcatheter intraarterial first-pass perfusion (TRIP) magnetic resonance (MR) imaging can depict serial reductions in rabbit liver tumor perfusion during transcatheter arterial embolization (TAE). Materials and Methods: All experiments had institutional animal care and use committee approval. In four rabbits implanted with eight VX2 liver tumors, catheters were positioned in the hepatic arteries with conventional angiographic guidance. After transfer to the MR imaging suite, serial TAE was performed, with approximately 0.5 million 40-120-μm embolic particles injected at each embolic stage. TRIP MR imaging was performed at baseline and after each subsequent embolic stage (10 minutes between stages). Serial TAE and TRIP MR imaging were repeated until stasis. The first-pass time course of signal enhancement was measured in both tumors and hepatic arteries. Tumor area under the curve (AUC) and maximum upslope (MUS) values, each normalized by arterial input, were measured to assess iterative perfusion reduction. Perfusion measurements across TAE stages were compared with paired t tests and linear regression. Results: AUC decreased from a pre-TAE baseline of 0.408 (95% confidence interval [CI]: 0.330, 0.486) to 0.065 (95% CI: 0.046, 0.085) (P < .001) after TAE. MUS decreased from a pre-TAE baseline of 0.151 (95% CI: 0.121, 0.181) to 0.027 (95% CI: 0.022, 0.031) (P < .001) after TAE. Reductions to AUC and MUS after each embolic stage were statistically significant (P < .006 for each group of paired comparisons). AUC strongly correlated with MUS (r = 0.966, P < .001). Conclusion: TRIP MR imaging can depict serial reductions in liver tumor perfusion during TAE. TRIP MR imaging offers the potential to target functional embolic end points during TAE.

UR - http://www.scopus.com/inward/record.url?scp=34548691483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548691483&partnerID=8YFLogxK

U2 - 10.1148/radiol.2451061689

DO - 10.1148/radiol.2451061689

M3 - Article

C2 - 17885186

AN - SCOPUS:34548691483

VL - 245

SP - 130

EP - 139

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -